Related Experiment Video
Updated: Apr 21, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Small cell lung cancer: where do we go from here?
Lauren Averett Byers1, Charles M Rudin
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately 14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed annually with SCLC. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC has not changed significantly in the past several decades. Consequently, the 5-year survival rate remains low at <7% overall, and most patients survive for only 1 year or less after diagnosis. Unlike nonsmall cell lung cancer (NSCLC), in which major advances have been made using targeted therapies, there are still no approved targeted drugs for SCLC. Significant barriers to progress in SCLC include 1) a lack of early detection modalities, 2) limited tumor tissue for translational research (eg, molecular profiling of DNA, RNA, and/or protein alterations) because of small diagnostic biopsies and the rare use of surgical resection in standard treatment, and 3) rapid disease progression with poor understanding of the mechanisms contributing to therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent advances in current understanding of the underlying disease biology, and opportunities to advance translational research and therapeutic approaches for patients with SCLC.
Insights
Small cell lung cancer (SCLC) remains a deadly disease with limited treatment options and poor survival rates. This review highlights challenges and opportunities for advancing SCLC research and therapy.
Area of Science:
- Oncology
- Pulmonology
- Translational Research
Background:
- Small cell lung cancer (SCLC) constitutes 14% of lung cancer diagnoses, with over 31,000 cases annually in the US.
- Despite decades of research and numerous clinical trials, systemic treatments for SCLC have seen minimal improvement, leading to a low 5-year survival rate (<7%).
- Unlike non-small cell lung cancer (NSCLC), SCLC lacks approved targeted therapies, hindering progress.
Purpose of the Study:
- To review the current treatment landscape for SCLC.
- To discuss recent advancements in understanding SCLC biology.
- To identify opportunities for improving translational research and therapeutic strategies.
Main Methods:
- Literature review of current SCLC treatment approaches.
- Analysis of recent findings in SCLC disease biology.
- Identification of barriers and opportunities in translational research.
Main Results:
- SCLC treatment has remained largely unchanged for decades, with significant survival challenges.
- Barriers to progress include lack of early detection, limited tumor tissue for research, and poor understanding of resistance mechanisms.
- Recent biological insights offer potential avenues for novel therapeutic development.
Conclusions:
- Significant unmet needs persist in SCLC treatment and research.
- Overcoming barriers in early detection, tissue acquisition, and understanding resistance is crucial.
- Advancing translational research is key to developing effective targeted therapies for SCLC.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...